Agilent Technologies, Inc. (A) Stock Rating Upgraded by Zacks Investment Research

Agilent Technologies, Inc. (NYSE:A) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm presently has a $74.00 price target on the medical research company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 11.18% from the company’s previous close.

According to Zacks, “Agilent Technologies is a broad-based OEM of test and measurement equipment. The company’s fiscal second quarter results were above the Zacks Consensus estimate. Year to date, the stock has outperformed the Industry it belongs to. The company’s decision to divest/wind up underperforming businesses has enhanced its focus on the new Agilent, while enabling expansion of a solid recurring revenue base and diversification of geographic and industrial operations for growth. Also, the company’s focus on aligning investments so as to be oriented toward more attractive growth avenues and innovative high-margin product launches are positives. Agilent’s broad-based portfolio and increased focus on segments offer higher growth potential. However, the macro weakness in the U.S. and Europe and forex headwinds remain concerns.”

A has been the topic of several other research reports. Jefferies Group LLC restated a “buy” rating and issued a $66.00 target price on shares of Agilent Technologies in a research note on Wednesday, August 9th. Deutsche Bank AG reiterated a “buy” rating and set a $66.00 price target on shares of Agilent Technologies in a research report on Thursday, June 22nd. BidaskClub downgraded shares of Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Cowen and Company reiterated a “hold” rating and set a $65.00 price target on shares of Agilent Technologies in a research report on Thursday, September 28th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Agilent Technologies in a research report on Wednesday, August 16th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Agilent Technologies presently has an average rating of “Buy” and an average price target of $65.12.

Agilent Technologies (A) opened at 66.56 on Tuesday. The firm has a market capitalization of $21.42 billion, a price-to-earnings ratio of 34.33 and a beta of 1.30. Agilent Technologies has a 12 month low of $42.92 and a 12 month high of $66.77. The firm’s 50-day moving average is $64.78 and its 200 day moving average is $59.61.

Agilent Technologies (NYSE:A) last issued its earnings results on Tuesday, August 15th. The medical research company reported $0.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a net margin of 14.36% and a return on equity of 16.95%. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the company earned $0.49 EPS. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. Equities analysts predict that Agilent Technologies will post $2.32 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2017/10/10/agilent-technologies-inc-a-stock-rating-upgraded-by-zacks-investment-research.html.

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 16,492 shares of the company’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $65.33, for a total transaction of $1,077,422.36. Following the transaction, the chief executive officer now directly owns 211,872 shares in the company, valued at approximately $13,841,597.76. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Didier Hirsch sold 1,200 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $66.00, for a total transaction of $79,200.00. Following the transaction, the chief financial officer now owns 164,202 shares in the company, valued at $10,837,332. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 170,720 shares of company stock worth $10,795,039.

A number of institutional investors have recently added to or reduced their stakes in the business. Advisor Group Inc. increased its stake in shares of Agilent Technologies by 0.3% in the 2nd quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock valued at $235,000 after acquiring an additional 10 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in shares of Agilent Technologies by 0.8% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,658 shares of the medical research company’s stock valued at $276,000 after acquiring an additional 35 shares during the last quarter. Veritable L.P. increased its stake in shares of Agilent Technologies by 0.4% in the 2nd quarter. Veritable L.P. now owns 10,896 shares of the medical research company’s stock valued at $646,000 after acquiring an additional 40 shares during the last quarter. Park National Corp OH increased its stake in shares of Agilent Technologies by 1.1% in the 2nd quarter. Park National Corp OH now owns 4,077 shares of the medical research company’s stock valued at $242,000 after acquiring an additional 43 shares during the last quarter. Finally, Trust Co. of Vermont increased its stake in shares of Agilent Technologies by 1.8% in the 2nd quarter. Trust Co. of Vermont now owns 2,793 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 50 shares during the last quarter.

Agilent Technologies Company Profi

According to Zacks, “Agilent Technologies is a broad-based OEM of test and measurement equipment. The company’s fiscal second quarter results were above the Zacks Consensus estimate. Year to date, the stock has outperformed the Industry it belongs to. The company’s decision to divest/wind up underperforming businesses has enhanced its focus on the new Agilent, while enabling expansion of a solid recurring revenue base and diversification of geographic and industrial operations for growth. Also, the company’s focus on aligning investments so as to be oriented toward more attractive growth avenues and innovative high-margin product launches are positives. Agilent’s broad-based portfolio and increased focus on segments offer higher growth potential. However, the macro weakness in the U.S. and Europe and forex headwinds remain concerns.”

A has been the topic of several other research reports. Jefferies Group LLC restated a “buy” rating and issued a $66.00 target price on shares of Agilent Technologies in a research note on Wednesday, August 9th. Deutsche Bank AG reiterated a “buy” rating and set a $66.00 price target on shares of Agilent Technologies in a research report on Thursday, June 22nd. BidaskClub downgraded shares of Agilent Technologies from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Cowen and Company reiterated a “hold” rating and set a $65.00 price target on shares of Agilent Technologies in a research report on Thursday, September 28th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Agilent Technologies in a research report on Wednesday, August 16th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Agilent Technologies presently has an average rating of “Buy” and an average price target of $65.12.

Agilent Technologies (A) opened at 66.56 on Tuesday. The firm has a market capitalization of $21.42 billion, a price-to-earnings ratio of 34.33 and a beta of 1.30. Agilent Technologies has a 12 month low of $42.92 and a 12 month high of $66.77. The firm’s 50-day moving average is $64.78 and its 200 day moving average is $59.61.

Agilent Technologies (NYSE:A) last issued its earnings results on Tuesday, August 15th. The medical research company reported $0.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a net margin of 14.36% and a return on equity of 16.95%. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the company earned $0.49 EPS. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. Equities analysts predict that Agilent Technologies will post $2.32 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://ledgergazette.com/2017/10/10/agilent-technologies-inc-a-stock-rating-upgraded-by-zacks-investment-research.html.

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 16,492 shares of the company’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $65.33, for a total transaction of $1,077,422.36. Following the transaction, the chief executive officer now directly owns 211,872 shares in the company, valued at approximately $13,841,597.76. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Didier Hirsch sold 1,200 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $66.00, for a total transaction of $79,200.00. Following the transaction, the chief financial officer now owns 164,202 shares in the company, valued at $10,837,332. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 170,720 shares of company stock worth $10,795,039.

A number of institutional investors have recently added to or reduced their stakes in the business. Advisor Group Inc. increased its stake in shares of Agilent Technologies by 0.3% in the 2nd quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock valued at $235,000 after acquiring an additional 10 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in shares of Agilent Technologies by 0.8% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 4,658 shares of the medical research company’s stock valued at $276,000 after acquiring an additional 35 shares during the last quarter. Veritable L.P. increased its stake in shares of Agilent Technologies by 0.4% in the 2nd quarter. Veritable L.P. now owns 10,896 shares of the medical research company’s stock valued at $646,000 after acquiring an additional 40 shares during the last quarter. Park National Corp OH increased its stake in shares of Agilent Technologies by 1.1% in the 2nd quarter. Park National Corp OH now owns 4,077 shares of the medical research company’s stock valued at $242,000 after acquiring an additional 43 shares during the last quarter. Finally, Trust Co. of Vermont increased its stake in shares of Agilent Technologies by 1.8% in the 2nd quarter. Trust Co. of Vermont now owns 2,793 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 50 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply